Aligos Therapeutics, Inc. has announced its financial results for the third quarter of 2026, highlighting a reduced net loss and continued advancements in its clinical trials. The company is making significant strides in its efforts to develop therapies for chronic hepatitis B virus (HBV) infections, which is crucial for its growth and sustainability.

On November 6, 2026, Aligos issued a press release detailing its recent business progress and financial performance. This update is particularly important as it reflects the company's ongoing commitment to improving patient outcomes through innovative therapies.

Background

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California. The company operates under the Standard Industrial Classification (SIC) code 2836, which pertains to Biological Products, excluding diagnostic substances. Aligos is publicly traded on the Nasdaq under the ticker symbol ALGS. The firm focuses on developing therapies for liver and viral diseases, with a specific emphasis on chronic HBV infection.

What the Filing Says

The filing reveals that Aligos has made considerable progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium, which is on track for topline data readout in late Q3 2027. "With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout," stated Lawrence Blatt, Chairman and CEO of Aligos.

The financial results for the three months ending September 30, 2026, show a net loss of $21.9 million, or $(2.09) per share. This is a decrease from a net loss of $31.5 million, or $(3.04) per share, in the same quarter of the previous year. Research and development expenses were reported at $18.9 million, down from $23.9 million in Q3 2025, primarily due to reduced third-party expenses related to the clinical trial.

Impact

The financial results and clinical updates may significantly affect various stakeholders, including investors and patients. Investors will be keen to monitor Aligos' progress as it approaches key milestones in its clinical trials. Patients suffering from chronic HBV may benefit from the potential therapies being developed by Aligos, which could improve treatment options in the market.

What's Next

The filing does not specify what happens next, but the company is expected to continue its clinical trials and may provide further updates as it approaches the topline data readout for its ongoing studies.